https://www.selleckchem.com/pr....oducts/as1842856.htm
3CA and ABCC1 for Saudi CRC patients, especially given that the overexpression of PIK3CA mutations was previously linked with the lack of activity for the anti-EGFRs as first line treatment for CRC patients. The combination of HAA and 5FU has selectively sensitized the four CRC cells to 5FU and could be further studied. We have combined the PamChip kinase profiling of Saudi CRC samples with in vitro drug combination studies in four CRC cells, highlighting the importance of targeting PIK3CA and ABCC1 for Saudi CRC patients, especially
Like
Comment
Share